Key Highlights

  • NovoCure (NASDAQ:NVCR) said on November 9, 2026 that the FDA issued a not approvable letter for its premarket approval application for Optune Mya in brain metastases from non-small cell lung cancer.
  • The application sought approval for adults whose brain metastases had been treated with stereotactic radiation, adding the device after radiation to delay further spread in the brain.
  • The agency cited uncertainty about the degree of clinical benefit and did not raise safety concerns in its response to the company.
  • NovoCure plans to meet the FDA to discuss Options that would not require new clinical studies, though it cautioned there is no assurance of approval.

What the FDA Decided

A not approvable letter is a significant setback for NovoCure (NASDAQ:NVCR) because it means the agency does not believe the data submitted are enough to support approval in their current form. The company's device, which delivers tumour treating fields through electrodes worn on the scalp, is already approved for glioblastoma under the Optune brand, and the brain metastases application was intended to open a much larger patient population. Lung cancer is the most common source of brain metastases, and many patients receive focused radiation followed by monitoring, so an add-on therapy that delays progression could have broad use. The FDA's concern was the size of the benefit, not safety, which leaves room for discussion but also points to a core question about how convincing the trial results were. The ruling also removes a catalyst that investors had expected to add to growth in the coming years, and it adds to uncertainty over the company's medium-term plan.

The Path Forward

NovoCure said it is evaluating the FDA's feedback and wants to explore routes that would not require another trial, such as additional analyses of existing data, a narrower patient population or post-approval commitments. Device regulators have more flexibility than drug regulators in some cases, but a letter of this type is typically difficult to reverse without new evidence. The company has other programs to support growth. Optune Pax was approved in Japan for locally advanced pancreatic cancer on October 1, 2026, and NovoCure raised its 2026 guidance when it reported third-quarter results on October 29. That gives it continuing Revenue momentum in its existing markets while it works on the brain metastases decision. Management has not provided a timeline for the FDA meeting or for any resubmission, so the timing of a decision remains open.

Risks and What to Watch

The main risk is that NovoCure (NASDAQ:NVCR) cannot find a path to approval without a new study, which would delay the indication by several years and add cost. Investors had included brain metastases in long-term revenue models, so the letter reduces the expected size of the company's addressable market. Any similar concerns about the size of benefit could affect how regulators view other indications in development, including pancreatic cancer in the US. Investors should watch for the outcome of the planned FDA meeting, any statements on whether a resubmission is feasible, uptake of Optune Pax in Japan and progress in its US pancreatic cancer filing. How NovoCure communicates the regulatory path in coming weeks will shape investor confidence in its long-term plan.

Where Things Stand

NovoCure received an FDA not approvable letter for Optune Mya in brain metastases from lung cancer on November 9, 2026, with the agency citing uncertainty over the degree of clinical benefit rather than safety. The company will seek a path that avoids a new trial, but approval is not assured. Its existing glioblastoma Business and the Japan pancreatic approval continue to support revenue.